What are multi-omics? Why does our microbiome matter? What’s the difference between genetics and genomics? What is a digital twin? ISB and Seattle Science Foundation have partnered to create videos answering questions like these and more, showcasing ISB scientists and their work.
It’s Lyme disease season in many areas of the United States, including the Northeast, the Midwest, and some places on the West Coast. In our latest Research Roundtable event, ISB Associate Professor Dr. Naeha Subramanian discussed the latest Lyme disease research conducted in her lab.
Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.
GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.
While scientists have long studied bacterial infections, less attention has been paid to how the host immune response affects bacterial gene expression in the body. In a just-published paper in PNAS, ISB researchers detailed how the bacterium Salmonella conceals itself from the host immune system.
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.